


MCD 6-23-98



07-07-1998



100755535

T

Our Ref.: 121-78

Commissioner of Patents and Trademarks
Box Assignment, Washington, D.C. 20231

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): RTP Pharma Corporation</p> <p>Additional name/s of conveying party/ies attached? <input type="checkbox"/></p> <p>3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input checked="" type="checkbox"/> Security Assignment <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____</p> <p>Execution Date: <u>June 17, 1998</u></p>	<p>2. Name and address of receiving party(ies):</p> <p>Name: <u>CATO PHARMACANADA INC.</u> Internal Address: _____ Street Address: <u>9900 Boul. Cavendish, Suite 201</u> _____ _____ City: <u>Saint-Laurent, Quebec</u> State/Country: <u>Canada</u> Zip: <u>H4M 2V2</u></p> <p>Additional name/s & address/es attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>
---	--

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____

<p>A. Patent Application No(s). (1) _____ (2) _____ (3) _____</p>	<p>B. Patent No(s). (1) 4,622,219 (2) 4,725,442 (3) 5,091,187</p>
--	--

Additional numbers attached Yes No

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Name: <u>Arthur R. Crawford</u></p> <p>Internal Address: _____</p> <p>Street Address: <u>Nixon & Vanderhye P.C.</u> <u>1100 North Glebe Road</u> <u>8th Floor</u> City: <u>Arlington</u> State: <u>VA</u> Zip: <u>22201</u></p>	<p>6. Total number of applications & patents involved: <u>8</u></p> <p>7. Total fee (37 CFR 3.41) \$ <u>320.00</u> <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Authorized to be charged to deposit account #14-1140</p> <p>8. The Commissioner is hereby authorized to charge any <u>deficiency</u> in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper thereafter filed in this application by this firm) to our Account No. 14-1140.</p>
---	---

07/07/1998 DCDATES 00000012 4622219
01 FC-501 320.00 CP

DO NOT USE THIS SPACE

9. Statements and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Arthur R. Crawford *Arthur R. Crawford* June 23, 1998
Name of Person Signing Signature Date
Reg. No. 25,327

Total number of pages including original cover sheet, attachments, and document: [17]

RECORDATION FORM COVER SHEET

PATENTS ONLY

Our Ref.: 121-78

Commissioner of Patents and Trademarks
Box Assignment, Washington, D.C. 20231

1. Name of conveying party(ies):

2. Name and address of receiving party(ies):

Name: Societe Innovatech Du Grand Montreal
Street Address: 2020 University Avenue, Suite 1527
City: Montreal, Quebec
State: Canada
Zip: H3A 2A5

Name: Sofinov Societe Financiere D'Innovation Inc.
Street Address: 1981 Avenue McGill College, 7th Floor
City: Montreal, Quebec
State: Canada
Zip: H3A 3C7

Name: Biocapital Investments Limited Partnership
Street Address: 2540 Daniel-Johnson Boulevard, Suite 910
City: Laval, Quebec
State: Canada
Zip: H7T 2S3

Name: Industries Devma Inc.
Street Address: 600 de La Gauchetiere St. West, Suite 1700
City: Montreal, Quebec
State: Canada
Zip: H3B 4L8

Name: Monksland Holdings, B.V.
Street Address: Burgmeester Rijnderslaan 10, 1885 NC Amstelveen, P.O. Box 74500
City: 1070 DB Amsterdam
State: The Netherlands
Zip:

4. Application number(s) or patent number(s):

A. Patent Application No(s).

- (4)
- (5)
- (6)
- (7)
- (8)
- (9)

B. Patent No(s).

- (4) 5,091,188
- (5) 5,246,707
- (6) 5,637,625
- (7) 5,660,858
- (8) 5,681,816
- (9)

FROM :

1998.06-22 12:13 #128 P.22

**PATENT COLLATERAL ASSIGNMENT
(ISSUED U.S. PATENTS)**

This Agreement is made on the 17th day of June 1998 between, RTP Pharma Corporation, a North Carolina corporation having a mailing address at 4364 S. Alston Avenue, Durham, North Carolina 27713 (the "Assignor"), and the persons listed on Schedule A attached hereto (the "Initial Holders") and such other persons who become holders of the Notes described below.

BACKGROUND.

Each of the Initial Holders, other than Cato PharmaCanada, a Canadian corporation ("CatoPharma"), pursuant to an Investment Agreement of even date herewith (each an "Investment Agreement"), among RTP Pharma Inc., a Canadian corporation (the "Borrower"), the Assignor, The Cyclosporine Company Limited, an Irish corporation ("TCC"), and such Initial Holder, and CatoPharma, pursuant to an Investment Agreement of even date herewith (the "Discount Agreement"), among the Borrower, the Assignor, TCC, Cato Holding Company, a North Carolina corporation and the parent of CatoPharma, and CatoPharma, have agreed to purchase senior secured convertible promissory notes (the "Notes") to be issued by the Borrower for the purpose of financing the business and operations of the Borrower and its affiliates. The Borrower is the owner of all of the outstanding shares of Class A Common Stock of the Assignor, and as a condition precedent to their purchase of the Notes under their respective Investment Agreements (in the case of CatoPharma, the Discount Agreement), the Initial Holders have required that the Assignor execute and deliver a guaranty of even date herewith (the "Guaranty"), pursuant to which the Assignor has guaranteed certain obligations of the Borrower. As a further condition precedent to their purchase of the Notes under their respective Investment Agreements (in the case of CatoPharma, the Discount Agreement), the Initial Holders have required that the Assignor execute and deliver a security agreement of even date herewith (the "Security Agreement"), to secure the payment and performance by the Assignor of its obligations under the Guaranty, pursuant to which the Assignor has agreed to assign to the Holders (as that term is defined in the Security Agreement) certain patent rights. The Investment Agreements, the Discount Agreement, the Notes, the Guaranty, the Security Agreement, this Agreement, and the Patent Collateral Assignment (Pending U.S. Patent Applications) of even date herewith, among the Assignor and the Initial Holders, are collectively referred to as the "Transaction Documents".

NOW, THEREFORE, in consideration of the premises, the Assignor hereby agrees with the Holders as follows:

1. To secure the complete and timely satisfaction of all Secured Obligations (as defined in the Security Agreement), the Assignor hereby grants, assigns and conveys to the Holders the entire right, title and interest in and to the patent applications and patents listed in Schedule B hereto, including without limitation all proceeds thereof (such as, by way of example, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof (collectively called the "Patents").

PATENT

FROM :

1998.06-22 12:13 #129 P.23

2. The Assignor agrees that, until all of the Secured Obligations shall have been satisfied in full, it will not enter into any agreement (for example, a license agreement) which is inconsistent with the Assignor's obligations under this Agreement, without the Holders' prior written consent.

3. If, before the Secured Obligations shall have been satisfied in full, the Assignor shall obtain rights to any new patentable inventions, or become entitled to the benefit of any patent application or patent for any reissue, division, continuation, renewal, extension, or continuation-in-part of any Patent or any improvement on any Patent, the provisions of paragraph 1, shall automatically apply thereto and the Assignor shall give to the Holders prompt notice thereof in writing hereof.

4. The Assignor authorizes the Holders to modify this Agreement by amending Schedule A to include any future patents and patent applications which are Patents under paragraph 1 or paragraph 3 hereof.

5. Unless and until there shall have occurred and be continuing an event of default under the Transaction Documents, the Holders hereby grant to the Assignor the exclusive, nontransferable right and license under the Patents to make, have made for it, use and sell the inventions disclosed and claimed in the Patents for the Assignor's own benefit and account and for none other. The Assignor agrees not to sell or assign its interest in, or grant any sublicense under, the license granted to the Assignor in this paragraph 5, without the prior written consent of the Holders.

6. If any event of default under the Transaction Documents shall have occurred and be continuing, the Assignor's license under the Patents as set forth in paragraph 5, shall terminate forthwith, and the Holders shall have, in addition to all other rights and remedies given them by this Agreement, those allowed by law and the rights and remedies of a secured party under the Uniform Commercial Code as enacted in any jurisdiction in which the Patents may be located and, without limiting the generality of the foregoing, the Holders may immediately, without demand of performance and without other notice (except as set forth next below) or demand whatsoever to the Assignor, all of which are hereby expressly waived, and without advertisement, sell at public or private sale or otherwise realize upon, in Durham, North Carolina, or elsewhere, the whole or from time to time any part of the Patents, or any interest which the Assignor may have therein, and after deducting from the proceeds of sale or other disposition of the Patents all expenses (including all reasonable expenses for brokers, fees and legal services), shall apply the residue of such proceeds toward the payment of the Secured Obligations. Any remainder of the proceeds after payment in full of the Secured Obligations shall be paid over to the Assignor. Notice of any sale or other disposition of the Patents shall be given to the Assignor at least five (5) days before the time of any intended public or private sale or other disposition of the Patents is to be made, which the Assignor hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition, any Holder may, to the extent permissible under applicable law, purchase the whole or any part of the Patents sold, free from any right of redemption on the part of the Assignor, which right is hereby waived and released.

7. If any event of default under the Transaction Documents shall have occurred and be continuing, the Assignor hereby authorizes and empowers the Holders to make, constitute and appoint any officer or agent of the Holders, as the Holders may select in their exclusive

PATENT

6/22/98 12:36p

REEL: 9279 FRAME: 0986

FROM :

1998.06-22 12:14 #128 P.24

discretion, as the Assignor's true and lawful attorney-in fact, with the power to endorse the Assignor's name on all applications, documents, papers and instruments necessary for the Holders to use the Patents, or to grant or issue any exclusive or nonexclusive license under the Patents to any third person, or necessary for the Holders to assign, pledge, convey or otherwise transfer title in or dispose of the Patents to any third person. The Assignor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney shall be irrevocable for the life of this Agreement.

8. At such time as the Assignor shall completely satisfy all of the Secured Obligations, this Agreement shall terminate and the Holders shall execute and deliver to the Assignor all deeds, assignments and other instruments as may be necessary or proper to re-vest in the Assignor full title to the Patents, subject to any disposition thereof which may have been made by the Holders pursuant hereto.

9. Any and all fees, costs and expenses, of whatever kind or nature, including the reasonable attorney's fees and legal expenses incurred by the Holders in connection with the preparation of this Agreement and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining or preserving the Patents, or in defending or prosecuting any actions or proceedings arising out of or related to the Patents, shall be borne and paid by the Assignor on demand by the Holders and until so paid shall be added to the principal amount of the Secured Obligations and shall bear interest at the rate prescribed in the Security Agreement.

10. The Assignor shall have the duty, through counsel acceptable to the Holders, to prosecute diligently any patent applications of the Patents pending as of the date of this Agreement or thereafter until the Secured Obligations shall have been paid in full, to make application on unpatented but patentable inventions and to preserve and maintain all rights in patent applications and patents of the Patents, including without limitation the payment of all maintenance fees. Any expenses incurred in connection with such an application shall be borne by the Assignor. The Assignor shall not abandon any right to file a patent application, or any pending patent application or patent without the consent of the Holders, which consent shall not be unreasonably withheld.

11. The Assignor shall have the right, with the consent of the Holders, which shall not be unreasonably withheld, to bring suit to its own name, and to join the Holders, if necessary, as a party to such suit so long as the Holders are satisfied that such joinder will not subject any of them to any risk of liability, to enforce the Patents and any licenses thereunder. The Assignor shall promptly, upon demand, reimburse and indemnify the Holders for all damages, costs and expenses, including legal fees, incurred by the Holders pursuant to this paragraph 11.

12. No course of dealing between the Assignor and the Holders, nor any failure to exercise, nor any delay in exercising, on the part of the Holders, any right, power or privilege hereunder or under the Transaction Documents shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

PATENT

REEL: 9279 FRAME: 0987

6/22/98 12:36p

FROM :

1998.06-22 12:15 #128 P.25

13. All of the Holders' rights and remedies with respect to the Patents, whether established hereby or by the Transaction Documents, or by any other agreements or by law shall be cumulative and may be exercised singularly or concurrently.

14. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any clause or provision of this Agreement in any jurisdiction.

15. This Agreement is subject to modification only by a writing signed by the parties, except as provided in paragraph 4.

16. The benefits and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.

17. The validity and interpretation of this Agreement and the rights and obligations of the parties shall be governed by the laws of the State of North Carolina.

18. The exercise by the Holders of their rights hereunder shall be governed by and subject to the terms of an intercreditor agreement dated as of even date herewith by and among the Initial Holders, as the same may be amended from time to time.

(Signatures on the following page)

PATENT

FROM :

1998.06-22

12:16

#128 P.28

FROM :

WITNESS the execution hereof under seal as of the day and year first above written.

ATTEST-CORPORATE SEAL

ASSIGNEE

RTP PHARMA CORPORATION

By: [Signature]
Gary W. Pace, President

INITIAL HOLDERS

CATO PHARMACANADA, INC.

By: [Signature]
Allen E. Cato, President

INDUSTRIES DEVIKA INC.

By: _____
Its: _____

SOCIÉTÉ INNOVATECH DU GRAND
MONTREAL

By: _____
Its: _____

SOFINOV SOCIÉTÉ FINANCIÈRE
D'INNOVATION INC.

By: _____
Its: _____

BIOCAPITAL INVESTMENTS
LIMITED PARTNERSHIP
By BioCapital Management Inc.,
its general partner

By: _____
Its: _____

MONKSLAND HOLDINGS, B.V.

By: _____
Its: _____

W:\POLA\STPCMS\CONVERT\PROJECT - AG

FROM :

1998-06-22 12:15 #129 P.25

WITNESS the execution hereof under seal as of the day and year first above written.

ATTEST-CORPORATE SEAL

ASSIGNOR

RTP PHARMA CORPORATION

By: _____
Gary W. Pace, President

INITIAL HOLDERS

CATO PHARMACANADA, INC.

INDUSTRIES DEVMA INC.

By: Allen E. Cato
Allen E. Cato, President

By: _____
Its: _____

By: _____
Its: _____

**SOCIÉTÉ INNOVATECH DU GRAND
MONTREAL**

**SOFINOV SOCIÉTÉ FINANCIÈRE
D'INNOVATION INC.**

By: _____
Its: _____

By: _____
Its: _____

By: _____
Its: _____

**BIOCAPITAL INVESTMENTS
LIMITED PARTNERSHIP
By BioCapital Management Inc.,
its general partner**

MONESLAND HOLDINGS, B.V.

By: _____
Its: _____

By: [Signature]
Its: DIRECTOR

R:\MARK\89949\CONV\89949.PATENT.12.A90

FROM :

1998-06-22 12:16 #128 P.29

FROM :

1998-06-17 12:28 #248 P.23

WITNESS the execution hereof under seal as of the day and year first above written.

ATTEST-CORPORATE SEAL

ASSIGNEE

RTP PHARMA CORPORATION

By: _____
Guy W. Pass, President

INITIAL HOLDERS

CATO PHARMACANADA, INC.

INDUSTRIES DEVMA INC.

By: _____
Alan E. Cato, President

By: _____
Inc.
By: _____
Inc.

SOCIÉTÉ INNOVATECH DU GRAND
MONTREAL

SOFINOV SOCIÉTÉ FINANCIÈRE
D'INNOVATION INC.

By: _____
Inc.

By: _____
Inc.

By: _____
Inc.

BIOCAPITAL INVESTMENTS
LIMITED PARTNERSHIP

MONKLAND HOLDINGS, B.V.

By BioCapital Management Inc.,
its general partner

By: _____
Inc.

By: _____
Inc.

06/22/98 12:36

FROM :

1998, 06-22 12:17 #128 P.32

FROM :

1998, 06-17 15:47 #543 P.06

WITNESS the execution hereof under seal as of the day and year first above written.

ATTEST-CORPORATE SEAL

ASSIGNOR

RTP PHARMA CORPORATION

By: _____
Gary W. Pace, President

INITIAL HOLDERS

CATO PHARMACANADA, INC.

INDUSTRIES DEVMA INC.

By: _____
Allen E. Cato, President

By: _____
Its:

By: _____
Its:

SOCIÉTÉ INNOVATECH DU GRAND
MONTREAL

SOFINOV SOCIÉTÉ FINANCIÈRE
D'INNOVATION INC.

By: *[Signature]*
Its: *Pres & CEO*

By: _____
Its:

By: _____
Its:

BIOCAPITAL INVESTMENTS
LIMITED PARTNERSHIP
By BioCapital Management Inc.,
its general partner

MONKSLAND HOLDINGS, B.V.

By: _____
Its:

By: _____
Its:

FROM :

06/22/98 11:18 FAX 514 847 2920

1998.06-22

12:17

#128 P.33

1998.06-17

15:51

#544 P.05

FROM :

WITNESS the execution hereof under seal as of the day and year first above written:

ATTEST-CORPORATE SEAL

ASSIGNEE

RTP PHARMA CORPORATION

By: _____
Gary W. Pass, President

INITIAL HOLDERS

CATO PHARMACANADA, INC.

INDUSTRIES DEVMA INC.

By: _____
Allen E. Cato, President

By: _____
Its:

By: _____
Its:

SOCIÉTÉ INNOVATECH DU GRAND MONTREAL

SOFINOV SOCIÉTÉ FINANCIÈRE D'INNOVATION INC.

By: _____
Its:

By: _____
Its:

By: _____
Its: Vice-President

BIOCAPITAL INVESTMENTS LIMITED PARTNERSHIP
By BioCapital Management Inc., its general partner

MONKSLAND HOLDINGS, B.V.

By: _____
Its:

By: _____
Its:

FROM :

1998.06-22 12:17 #128 P.34

SCHEDULE A**INITIAL HOLDERS**

CATO PHARMACANADA INC., a body politic and corporate, duly incorporated under the Canada Business Corporations Act, having its head office in the City of Montreal, Province of Quebec (hereinafter referred to as "CatoPharma")

AND: SOCIÉTÉ INNOVATECH DU GRAND MONTRÉAL, a body politic duly constituted by *An Act respecting Société Innovatech du Grand Montreal*, R.S.Q., ch. S-17.2, having its head office in the City of Montreal, Province of Quebec (hereinafter referred to as "Innovatech")

AND: SOFINOV SOCIÉTÉ FINANCIÈRE D'INNOVATION INC., a body politic and corporate, duly incorporated under the *Companies Act* (Quebec), having its head office in the City of Montreal, Province of Quebec (hereinafter referred to as "Sofinov")

AND: BIOCAPITAL INVESTMENTS LIMITED PARTNERSHIP, a limited partnership constituted under the laws of the Province of Quebec, having its head office in the City of Laval, Province of Quebec, herein acting through and represented by its general partner BioCapital Management Inc. (hereinafter referred to as "BioCapital")

AND: INDUSTRIES DEVMA INC., a body politic and corporate, duly incorporated under the laws of the Province of Quebec, having its head office in the City of Montreal, Province of Quebec (hereinafter referred to as "Devma")

AND: MONKSLAND HOLDINGS, B.V., a body politic and corporate, duly incorporated under the laws of The Netherlands, having its head office in the City of Amstelveen (hereinafter referred to as "Monksland")

PATENT

FROM :

1998.06-22 12:18 #128 P.35

NOTICE ADDRESSES OF THE ASSIGNOR AND THE INITIAL HOLDERS

if to the Guarantor: **RTP PHARMA CORPORATION**
4364 S. Alston Avenue
Durham, North Carolina
27713, U.S.A.

Attention: Gary W. Pace
Telecopier: (919) 361-2859

if to CatoPharma: **CATO PHARMACANADA INC.**
9900 Boul. Cavendish
Suite 201
Saint-Laurent, Quebec
H4M 2V2

Attention: Allen Cato
Telecopier: (514) 856-0100

if to Sofinov: **SOFINOV SOCIÉTÉ FINANCIÈRE D'INNOVATION INC.**
1981 Avenue McGill College, 7th Floor
Montreal, Quebec
H3A 3C7

Attention: President
Telecopier: (514) 847-2628

if to Innovatech: **SOCIÉTÉ INNOVATECH DU GRAND MONTRÉAL**
2020 University Avenue, Suite 1527
Montreal, Quebec
H3A 2A5

Attention: President
Telecopier: (514) 864-4220

if to BioCapital: **BIOCAPITAL INVESTMENTS LIMITED PARTNERSHIP**
2540 Daniel-Johnson Boulevard, Suite 910
Laval, Quebec
H7T 2S3

Attention: President
Telecopier: (514) 687-9283

if to Devma: **INDUSTRIES DEVMA INC.**
600 de La Gauchetière St. West, Suite 1700
Montreal, Quebec

FROM :

1998.06-22 12:18 #128 P.36

H3B 4L8

Attention: the Secretary
Telecopier: (514) 395-8055

if to Monksland

MONKSLAND HOLDINGS, B.V.
Burgmeester Rijnderslaan 10
1885 NC Amstelveen
P.O. Box 74500
1070 DB Amsterdam
The Netherlands

Attention: William Daniel
Telecopier: (31) 20-656-7700

with a copy in all cases to:

DANIELS & DANIELS, P.A.
1000 Park Forty Plaza
Durham, North Carolina
U.S.A. 27713

Attention: Walter E. Daniels
Telecopier: (919) 544-5920

with a copy in all cases to:

LAPOINTE ROSENSTEIN
1250 René-Lévesque Blvd. West, Suite 1400
Montreal, Quebec
H3B 5E9

Attention: Me Perry Klot
Telecopier: (514) 925-9001

with a copy in all cases to:

MCCARTHY TÉTRAULT
Le Windsor
1170 Peel Street, 5th floor
Montreal, Quebec
H3B 4S8

Attention: Me Peter S. Martin
Telecopier: (514) 875-6246

with a copy in all cases to:

BOIVIN O'NEIL, S.E.N.C.
2000 Mansfield Street, Suite 1300
Montreal, Quebec
H3A 3A1

Attention: Me Valier Boivin
Telecopier: (514) 844-5836

FROM :

1998, 06-22

12:10

#128 P.37

with a copy in all cases to:

**BROCK, FENSTERSTOCK, SILVERSTEIN,
McAULIFFE & WADE, LLC**
56th Floor
One Citicorp Center
New York, NY 10022-4611
U.S.A.

Attention: David Robbins
Telecopier: (212) 371-5500

FROM :

1998.06-22

12:19

#128 P. 39

SCHEDULE B

Application or Patent No.	Country	Issue or Filing Date	Expiration Date	Title
4,622,219	U.S.	November 11, 1986	November 11, 2003	Method of Inducing Local Anaesthesia Using MicroDroplets of a General Anaesthetic
4,725,442	U.S.	February 2, 1988	April 22, 2006	MicroDroplets of Water-insoluble Drugs and Injectable Formulations Containing Same.
1,242,645	Canada	April 10, 1988		" "
153,926	EPO (Austria, Belgium, France, Great Britain, Luxembourg, Netherlands, Sweden, Switzerland, Germany)	February 16, 1991		" "
2,518,605	Japan	May 17, 1996		" "
5,091,187	U.S.	February 25, 1992	May 21, 2011	Phospholipid-Coated MicroCrystals Injectable Formulation of Water-Insoluble Drugs
5,091,188	U.S.	February 25, 1992	April 26, 2010	Phospholipid-coated MicroCrystals Injectable Formulations of WaterInsoluble Drugs
2,078,990	Canada	April 23, 1991		" "
91908933.4	EPO	April 23, 1991		" "
173,056	India	April 22, 1991		" "
3-508854	Japan	April 23, 1991		" "
702656/92	Korea	April 23, 1991		" "
178176	Mexico	May 29, 1995		" "
92016352	Russia	April 23, 1991		" "

PATENT

REEL: 9279 FRAME: 0998

6/22/98 12:36p

FROM :

1998, 06-22 12:19 #128 P.39

61654	Taiwan	July 31, 1993		" "
91/3122	South Africa	April 29, 1992		" "
5,246,707	U.S.	September 21, 1993	February 25, 2009	Sustained Release Delivery of Water-Soluble Bio-Molecules and Drugs Using Phospholipid-Coated MicroCrystals, MicroDroplets and High Concentrations Liposomes
5,637,625	U.S.	June 10, 1997	March 19, 2016	Propofol MicroDroplets Formulations
PCT/US97/04168		March 17, 1997		" "
97301839.3	EPO	March 19, 1997		" "
5,660,858	U.S.	August, 26, 1997	April 3, 2016	Cyclosporin Emulsions
PCT/US97/04794		March 26, 1997		" "
97302298.1	EPO	April 3, 1997		" "
5,681,816	U.S.	October 28, 1997	February 22, 2014	Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
2,107,884	Canada	April 24, 1992		" "
92913717.2	EPO	April 24, 1992		" "
664,850	Australia	April 24, 1992		" "
51917	Japan	October 22, 1993		" "